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Abstract: Background 
During the last three decades a tremendous progress has been made in the discovery and development 
of a lot of new molecules in many pharmaceutical areas.  These families of real innovative treatment 
comprise of "originator" molecules (first molecule released, which can be under patent or with expired 
patent), as well "generic" version of those originator molecules, whose patent has expired. Usually the 
patent expires 15 to 20 years after the creation of the originator molecule.   
Main objective 
This research focuses on the effects of the arrival of generic and or therapeutic competitors on the 
market, in terms of impacts on the market share and prices.  
Methodology 
Between 2005 and 2007 we follow three classes of medicinal products in the cardiovascular area:ACE 
inhibitors, sartans and statins. They have been studied on the Bulgarian market because there is no 
regulation in the country stimulating the generic market. The official database of the Bulgarian Health 
Insurance Fund was used to test our two hypothesis concerning the impact of the generics on market 
share and prices. To test our hypothesis a t-test analysis, Kolmogorov Smirnov, one and two way 
ANOVA analyses were performed.  
Results 
Our results confirm that the generic competition, in general, changes the market. These changes 
decrease the medicines prices. 
The generic competition is not regulatory supported in the country and this fact could influence 
negatively our study because it does not correspond to the world tendencies. 
Furthermore our results confirm that the creation of sustainable generic pharmaceutical market 
requires active regulatory and marketing measures at all levels including incentives for manufactures, 
physicians and dispensers.  
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The authors have not implemented all recommendations.  
Some few remarks are the following: 
 
Methodology 
It is necessary to use the DDD (defined daily dose) system because it is the gold standard for 
international drug utilization research. The current results are burdened with bias. DDD describes a 
technical measurement and comparison unit. Compared with other measurement units, like the usage 
in mg for INN, the DDD has the advantage, that changes in the package size or dosage can not distort 
the measured consumption. Defined daily doses (DDDs) are a WHO statistical measure of drug 
consumption. Please calculate the DDDs for the studied drugs and then the outcome will be 
pharmaceutically correct and more therapeutically compatible. 
Dear Mr. Reviewer, 
As we answer in our previous correspondence the calculations using the DDD methodology are already 
in a process of analysis but some of the authors included in this manuscript are not participating 
within the other calculations and analysis, as well as some new colleagues have been included. We 
consider that it is not ethical to change now the teams during the evaluation process.  
We know the WHO methodology and it is really the gold standard, but we also found lots of articles 
using the approach of measuring the utilization in units of active ingredients, and especially in 
milligrams.  
The comments for the reasoning of such an approach are added in the discussion section, as follows 
also and below: 
   
Comment is added in the discussion section as follows: Comparison of the market share and prices in 
milligrams has its own reasoning for international market tender purposes (Al-Abbadi 2009; Karam R. 
2010; Zaheer 2007), as well as for reference prices comparison.  
Such a price comparison per milligram of active substance is also regularly performed by the 
Management science for health and World health organisation when they publish the International 
Drug Price Indicator Guide and all prices are shown per milligrams of active substance (Frye 2007).  
Some countries are using the generics' price per milligrams in the process of establishment of the 
lowest price per product within the reimbursement system (Mrazek 2002).  
Other authors consider (WHO 2003) that, if medicines utilization is given in terms of grams of active 
ingredients, drugs with low potency will account for a larger fraction of the total than drugs with high 
potency, and that the combined products may also change their market figure. In our study we did not 
observe any combination so our figures could not be affected by such an utilization data. We also did 
not observe significant changes in the prices per milligram for the medicines with different potency, 
thus this is not also the case for consideration. 
The international prices comparison per milligrams of active substance could be used by the 
regulatory authorities.  Grootendorst (2001) analysed the impact of referenced - based pricing on 
nitrates usage and cost reduction by using also the cost per milligram. Similar approach was found 
useful in case of comparison of the medicines prices for particular therapeutic groups (Wang 2008) , 
which is also the case in our study.  
 
Introduction 
Line 9: Please correct ".such as Angiotensin-Converting Enzyme (ACE inhibitors)." to "such as 
inhibitors of Angiotensin-Converting Enzyme (ACE inhibitors).".- it is done 
Line 13: The point is missing. - it is done 
Line 27: Please remove the word "new" from sentence "To give an example, a new molecule, the 
ramipril,." because ramipril is an already known ACE inhibitor. - it is done 
 
Conceptual framework and Literature review 
Line 6: Please give the bibliographical reference for "... and from some of them more than a thousand 
generic products have originated." . It is changed to: "lots of generic products have originated" 
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Line 23: Please correct ".influencing the generic medicines market." to ".influencing the generic 
medicine market.". It is changed 
 
Main objective 
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Methods 
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appendix. Done 
Please take the same spelling for the word "mg" in the whole article. Corrected 
Line 45: Please delete "Furthermore" because two following sentences have the same beginning. Done 
Line 2: These two sentences are inconsistent: "In the group of sartans generic competitors were 
available only for losartan." (line 2, page 10), "Within the group of sartans, 
valsartan and losartan have expired patents and generics available on the market"(line 17, page 8). 
Please check this. Checked and removed 
Line 2:  "In the group of sartans generic competitors were available only for losartan.": Please write  "In 
the group of sartans generic competitors were only available for losartan.". Changed 
Results 
Line 12: Please correct "ACE Inhibitors" to "ACE inhibitors" and take the same spelling in the whole 
article. Done 
Line 14: Please write ".and the generics for ramipril.". Done 
Line 16: These two sentences are inconsistent: "In the therapeutic class of statins we also found 4 INNs 
with generics: the simvastatin, pravastatin, atorvastatin and the lovastatin." (line 16, page 10), "The 
statins therapeutic group is composed of 6 molecules from which 3 have expired patent." (line 24, page 
8). Please check this. Done 
 
Analysis of the market share of products 
Line 26: Considering grammar you should write ".when we begun our study." instead of ".when we 
begin our study.". Corrected 
Line 1: Please correct ".after the introduction of the generic competitor to lisinopril in 2006" to ".after 
the introduction of the generic competitors to lisinopril in 2006". Corrected 
Line 46: Please write ". in market share of the belonging INNs". Corrected 
Line 52: Please take the same spelling for the word "National health insurance fund".  
Table 4 and Appendix 1 Corrected 
 
Considering the word "BGL" you should write "BGN" because the ISO 4217 currency code for the new 
Bulgarian lev is BGN Corrected. 
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Dear Mr. Reviewer, 
As we answer in our previous correspondence the calculations using the DDD methodology are already 
in a process of analysis but some of the authors included in this manuscript are not participating 
within the other calculations and analysis, as well as some new colleagues have been included. We 
consider that it is not ethical to change now the teams during the evaluation process.  
We know the WHO methodology and it is really the gold standard, but we also found lots of articles 
using the approach of measuring the utilization in units of active ingredients, and especially in 
milligrams.  
The comments for the reasoning of such an approach are added in the discussion section, as follows 
also and below: 
 
Comparison of the market share and prices in milligrams has its own reasoning for international 
market tender purposes (Al-Abbadi 2009; Karam R. 2010; Zaheer 2007), as well as for reference prices 
comparison.  
Such a price comparison per milligram of active substance is also regularly performed by the 
Management science for health and World health organisation when they publish the International 
Drug Price Indicator Guide and all prices are shown per milligrams of active substance (Frye 2007).  
Some countries are using the generics' price per milligrams in the process of establishment of the 
lowest price per product within the reimbursement system (Mrazek 2002).  
Other authors consider (WHO 2003) that, if medicines utilization is given in terms of grams of active 
ingredients, drugs with low potency will account for a larger fraction of the total than drugs with high 
potency, and that the combined products may also change their market figure. In our study we did not 
observe any combination so our figures could not be affected by such an utilization data. We also did 
not observe significant changes in the prices per milligram for the medicines with different potency, 
thus this is not also the case for consideration. 
The international prices comparison per milligrams of active substance could be used by the 
regulatory authorities.  Grootendorst (2001) analysed the impact of referenced - based pricing on 
nitrates usage and cost reduction by using also the cost per milligram. Similar approach was found 
useful in case of comparison of the medicines prices for particular therapeutic groups (Wang 2008) , 
which is also the case in our study.  
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Introduction 
 
During the last three decades a tremendous progress has been made in the discovery and 
development of a lot of new molecules in many pharmaceutical areas. The therapeutic groups 
of cardiovascular medicines, such as inhibitors of Angiotensin-Converting Enzyme (ACE 
inhibitors), sartans and statins, are good examples of the aforementioned development and 
creation of therapeutic families (Fyhrquist and Saijonmaa 2008; Raizada and Ferreira 2007). 
These families of real innovative treatment comprise of “originator” molecules (first molecule 
released, which can be under patent or with expired patent), as well “generic” version of those 
originator molecules, whose patent has expired. Usually the patent expires 15 to 20 years after 
the creation of the originator molecule. These last products (what we call “generics”) have the 
same chemical structure and have been proven to be essentially similar in bioavailability 
(Morgan et al. 2005). 
To give an example, a molecule, the ramipril, in the family of ACE inhibitors has been 
launched by the pharmaceutical laboratory SANOFI AVENTIS under the name of Triatec

.  
When the patent of this product has expired, a competitor, the pharmaceutical laboratory 
QUALIMED launched the same product in terms of molecule and effects, so, a generic, 
called Ramipril Qualimed

. However, within the same therapeutic group, MSD had already 
launched enalapril under the name of Renitec
 
 that is a “therapeutic competitor”, possessing 
small variation in the chemical structure. Following the same approach of modification of the 
first molecule the perindopril, trandolapril, fosinopril and so on were later developed and thus 
the whole therapeutic family started to expand.    
 
Conceptual framework and Literature review 
The generics create competition and drive medicine prices down (Lee 2004). Many studies 
show in fact that when a new medicinal product (a new molecule giving an originator or the 
same molecule giving a generic) appears on the pharmaceutical market, it affects the market 
patterns as well as prices of the existing generic and/or therapeutic competitors (Dirach 2000). 
To what extent and for how long time it happens depends on the specific characteristics of the 
national market, the laws concerning the generics and the pharmaceutical companies’ policy. 
Blinded Manuscript
Click here to view linked References
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A common perception is that the original medicinal product ensures new therapeutic options 
for severe diseases, while the generic medicines support the sustainability of healthcare 
provision and contribute to the maintaining of control over the pharmaceutical expenditure 
(Fiona 1997).  
Some countries use laws to promote the prescription and the delivery of generics, which leads 
to a decrease in the health expenditures. Studies focusing on the market policy of the 
pharmaceutical manufacturers consider that every new product, within the same therapeutic 
class, is characterised by simultaneous entry of competitors rather than sequential (Fiona 
1997). Basically, what this means is that the expiration of a product patent is accompanied by 
the simultaneous entry, sometimes the same day, of a different generic. Models have been 
created to calculate the aggregated demand and supply features, influencing the generic 
medicine market (Gascon et al. 2007). 
During the last two decades a reference pricing approach was developed, which began to be 
used in a lot of European countries
 
(Huttin 2002). The reference prices are established after an 
international or national comparison of prices of the generic or therapeutic alternatives 
(Mestre 2003). The reference price could be either the lowest or the average price within the 
compared group of products (Mrazek 2002). This policy stimulates research in the area of 
price comparison and analysis of the factors influencing price changes, as are the generics’ 
policy and competition. 
The cardiovascular medicines are of a particular interest for studying the competition between 
originators and generics. They are one of the leading therapeutic classes on the global 
medicine market today, with more or less 10% of the market sales in value (WHO 2007). For 
this particular reason, this class presents a big interest for the pharmaceutical manufacturers 
and we can currently find new innovative products and new generics. This interest is also 
shared by the health authorities, which want to control the increasing expenditures, analysing 
their prescription and their usage and creating national rules for price control. 
In this cardiovascular category of treatment, three groups of therapeutics present a bigger 
interest due to the presence of innovative molecules and the arrival of generics: the families of 
inhibitors of Angiotensin-Converting Enzyme (ACE inhibitors), sartans and statins 
(drugs.com 2008; Luno et al. 2005; Rossi et al 2006; Levy 2005). 
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The ACE inhibitors appeared with the discovery of the captopril molecule in 1975 that was 
considered as a breakthrough, due to its novel mechanism of action and the revolutionary 
development process. Nowadays this therapeutic group includes 16 different molecules with a 
similar structure, and from some of them lots of generic products have originated (Rossi S 
(Ed.) 2009). Currently, only 2 molecules are still under patent protection. 
The sartans (also named “Angiotensin Receptor Blockers” or “Angiotensin II Receptor 
Antagonists”) modulate the rennin-angiotensin-aldosterone system and thus lead to a decrease 
in blood pressure. The tetrazole group is a main part of the chemical structure of losartan, 
irbesartan, olmesartan, candesartan and valsartan. In addition, losartan, irbesartan, olmesartan, 
candesartan and telmisartan include one or two imidazole groups. Within the group of sartans, 
valsartan and losartan have expired patents and generics available on the market. 
The statins are lipid lowering agents with first marketed INN lovastatin and soon after, the 
simvastatin was placed on the market (Stossel TP. 2008). The statins therapeutic group is 
composed of 6 molecules from which 4 have expired patent. 
 
Main objective  
The aim of this study was to analyse the changes in the drug usage and prices in these three 
pharmaco-therapeutic groups, acting on cardiovascular system, on the Bulgarian market 
between the years 2005-2007. 
 
Hypothesis tested 
Due to the fact that there is no law regulation on the generic medicines in Bulgaria, we want 
to test two hypotheses: 
Hypothesis 1: The introduction of new medicinal products (originators or generics) affects 
the sales data and/or market share within the group. 
Hypothesis 2: The introduction of new medicinal products (originators or generics) decreases 
the prices of the competitors within the group. 
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Methods 
Using the official National Health Insurance Fund’s database, we collected information for 
the prescription of 20 different INN in the cardiovascular classes of medicines: 9 ACE 
inhibitors, 5 sartans and 6 statins, authorized for sale on the Bulgarian market in the years 
2005-2007. 
A database was created, which included the prescribed packages of different trade names and 
dosage forms of medicinal products, sold under the observed 20 International Nonproprietary 
Names (INN). To summarise the differences between the packages, the usage was 
recalculated in milligrams for every INN during the particular year observed. 
The information for the drug prices was gathered from the official register of the Ministry of 
Health for all authorised trade names of observed medicines (Ministry of health 2005, 2006, 
2007). Then, the prices were recalculated, to establish the price per milligram for every 
dosage form and within the group of products under the same INN. To calculate the mean 
price per INN and per milligram a descriptive statistic was applied.  
 
To test the first hypothesis we first applied the Kolmogorov Smirnov (K-S) test towards the 
sales data during the observed years. The K-S test seeks differences between the distribution 
function of sales data in 2006 in comparison with 2005, and 2007 in comparison with 2006. 
The test provides information for the differences between the observed years by rejecting the 
null hypothesis if no differences exist. 
 
To analyse the possible differences among the sales data of particular INNs during the 
observed years, the market share of every INN, out of all sold milligrams of INNs within 
every therapeutic group, was recalculated. Furthermore, in a second step, we calculated the 
proportions, using the z-test analysis for every INN assuming 95% CI for the changes in 
proportions of INNs, comparing the data for the year 2005 versus the year 2006 and the year 
2006 versus the year 2007. The z-test provides information for the statistically significant 
differences among the proportions of INNs sold during the years 2005, 2006 and 2007.  
 
To test the second hypothesis, we first performed a two-way ANOVA analysis to evaluate the 
statistically significant differences between the prices of active substances, per milligram, for 
the products within each therapeutic group and during the observed years. If there was a 
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difference established we next perform a one way ANOVA analysis to evaluate them per 
INNs and among the therapeutic alternatives.  
 
Results 
Out of all collected medicinal products in the therapeutic class of ACE inhibitors, we found 3 
INNs with generics: the enalapril, lisinopril (during 2005-2007) and the generics for ramipril 
appears during the third year of observation (2007). In the therapeutic class of statins we also 
found 4 INNs with generics: the simvastatin, pravastatin, atorvastatin and the lovastatin. In 
the last therapeutic class studied, the sartans, we found 1 INN with a generic, the losartan. The 
other INNs within these three therapeutic groups are considered as therapeutic competitors. 
All these results are in Appendix 1. Some of the fields in Appendix 1 are marked with “0” due 
to the lack of sales data in the National Health Insurance Fund’s database for the particular 
year observed. 
 
Analysis of the market share of products 
In the product class of ACE inhibitors, the enalapril in milligrams is the leader of the class 
with 93.1 % of the market share in 2005 - when we begun our study. It’s not possible to see it 
in this appendix but the enalapril permanently increased its’ market share in the years before 
2005. The market share of enalapril decreased in 2006 (88.6 %), and 2007 (86.34 %) despite 
the introduction of new generics in 2006. 
All other products within the group, except the quinapril (which decreased in 2007 versus 
2006) perform a steady increase in their usage, measured in kg, of active substance sold 
(Appendix 1).  
We can say that the fast growth rate of the therapeutic group and introduction of 2 different 
new molecules within the class lead to a decrease in the market share of enalapril during 2006 
with 4,5 % and during 2007 with 2,24% (Figure 1). On the other hand, the market share of the 
therapeutic competitors slowly and permanently increases every year thus taking part of the 
enalapril market share.  
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It is also necessary to point out that after the introduction of the generic competitors to 
lisinopril in 2006, its market share increase with a bigger percentage (from 2.34 % in 2005 to 
3.65 % in 2006) than the share of the other therapeutic competitors within the group and this 
increase continued still, even after the exclusion of one of the products during the next year.  
Placed Here - Figure 1: Relative Market Share of ACE inhibitors sales during 2005, 2006 
and 2007. 
 
In the product class of sartans, the biggest market share in 2005 was that of telmisartan, 
probably because of the promotional price of the originator. In the second year the only one 
product with a generic version (losartan) increased its market share almost 6 times, thus 
taking a leading position in the group. 
The market dynamic in proportions of INNs sold within the group of sartans is mostly evident 
in comparison with the previous group, but we can suppose that these changes are contributed 
mainly to the active market development of the products within the group. 
 
Placed here - Figure 2: Relative Market Share of sartans sales during 2005, 2006 and 2007. 
 
The product class of statins is the most dynamic in terms of changes of generic and 
therapeutic competitors. In this group, we observed that after the increase of the number of 
generic competitors under the same INN, the relative market share of the INN increased - as 
is the case for simvastatin. We can consider that the introduction of new generics did not 
deprive the sales data of the originator immediately, but, in general, contributed to the 
accumulation in market share of the belonging INNs. In this group we also observed that the 
introduction of a new product affects the sales data of competitors, as is the case with the 
inclusion of  rosuvastatin.  
 
Placed here -  Figure 3: Relative Market Share of statins sales during 2005, 2006 and 2007. 
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After applying the Kolmogorov Smirnov test, we observed that there is a statistically 
significant difference among the sales data during 2006 and 2005, as well as during 2007 and 
2006 (Table 1). The test confirmed that the sales data of the observed therapeutic groups 
changed statistically significantly during the analysed years. 
 
Placed here – Table 1: Results of the Kolmogorov Smirnov test  
 
To test the differences among the INNs’ sales data, the z-test analysis was applied. The results 
of the z-test analysis confirm that for almost all the products, except for the perindopril and 
trandolapril in the class of ACE inhibitors, and irbesartan from class of sartans, the changes in 
the market share are statistically significant (Table 2). For all of these three products there is 
no generic competitor. So we can conclude that the introduction of generics changes the 
market share of the INNs and contributes to the changes in the share of the therapeutic 
groups. The changes in the market share products without generics could be explained with 
the marketing policy of the companies - a fact that was not explored in this study.  
Thus our first hypothesis is confirmed. 
 
Placed here – Table 2. Results of the z-test analysis 
 
Analysis of the price changes 
Concerning the prices, all of them decreased during the observed period from 2005 to 2007 
but it was mainly due to the changes in the regulation (Appendix 1) (Ministry of health, Drug 
price registry 2005, 2006, 2007). The regulatory changes affect mainly the decrease of the 
distributors’ margins (wholesale and retail), almost half for the medicines paid by the 
National Health Insurance Fund. 
For the group of ACE inhibitors, the two way ANOVA analysis confirms that the prices per 
milligram differed among the observed products (p<0.05), but did not differ statistically 
significant during the years for the whole group (p>0.05) (Table 3). Multiple comparison 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
among the prices of different INNs established statistically significant differences (p < 0.05) 
between the prices per milligram of trandolapril and all other INNs within the group 
(benazepril; cilazapril; enalapril; fosinopril; lisinopril; perindopril; quinapril and ramipril).  
The one way ANOVA analysis revealed significant differences (p < 0.05) in the prices during 
the years only for lisinopril (Table 4). It is necessary to point out that the mean price 
decreased in the year 2007, when one of the generics was excluded from the database, which 
was the most expensive one.  
The statines group included 6 INNs with 20 to 29 dosage forms per year. In this group, we 
also did not find significant price differences among the years (p>0.05), but prices of the 
INNs within the group differs (p<0.05) (Table 3). By applying multiple comparisons, the 
difference among lovastatin and rosuvastatin was evaluated as statistically significant. No 
differences among the prices for particular INNs were observed (Table 4). 
For the group of sartans, we also found, through the two way ANOVA analysis, that the 
prices per milligram differ among the observed products (p<0.05), but did not differ 
significantly during the observed years for the whole group (p>0.05) (Table 3). Multiple 
comparisons among the INNs within the therapeutic groups revealed significant price 
differences between telmisartan and eprosartan. No differences between the prices for 
particular INNs were evaluated separately (Table 4). 
The results from two way and one way ANOVA analysis revealed that there are no 
statistically significant changes in the prices of the observed INNs, except for lisinopril, but 
there are significant price differences between the therapeutic competitors within the groups.  
Thus our second hypothesis is not fully confirmed.  
 
Discussion, limitations and further research  
The cardiovascular medicine market characteristics are of importance for the national markets 
for a lot of reasons, for example: their permanently growing usage, progress in new molecules 
discovery, changes in life expectancy of the population, creation of the national rules for price 
control, and cost containment measures. 
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We do observe a dynamic national market of cardiovascular medicines that correspond to the 
world tendencies, but the competition is mostly evident at the therapeutic groups level than at 
the generic ones ( drugs.com. 2008). 
Our results confirm those of similar studies - that the generic competition, in general, changes 
the market in the observed country. These changes benefit the generic products and decrease 
the medicines’ prices. 
The generic competition is not regulatory supported in the country and this fact could 
influence negatively our study because it does not correspond to the world tendencies (Law 
on Medicinal products for human medicine 2007; Ministry of health 2005, 2006, 2007). 
Furthermore, our results confirm some other publications - that the creation of a sustainable 
generic pharmaceutical market requires active regulatory and marketing measures at all 
levels, including incentives for manufactures, physicians, and dispensers (Simoens and de 
Coster 2006; Adriaen et al 2008). It is not only sufficient to shorten the marketing 
authorisation process for generic medicines at a European level, but every country should 
perform its own measures as well.  
Our study possesses some limitations in terms of the fact that we compare the mean prices per 
milligram and not per Defined Daily Dose (DDD), which is more therapeutically compatible. 
Despite the fact that DDD is established in milligrams for most of the medicines, we consider 
that in the future such analysis should be done for the changes in prices per DDD. 
Comparison of the market share and prices in milligrams has its own reasoning for 
international market tender purposes (Al-Abbadi 2009; Karam R. 2010; Zaheer 2007), as well 
as for reference prices comparison.  
Such a price comparison per milligram of active substance is also regularly performed by the 
Management science for health and World health organisation when they publish the 
International Drug Price Indicator Guide and all prices are shown per milligrams of active 
substance (Frye 2007).  
Some countries are using the generics’ price per milligrams in the process of establishment of 
the lowest price per product within the reimbursement system (Mrazek 2002).  
Other authors consider (WHO 2003) that, if medicines utilization is given in terms of grams 
of active ingredients, drugs with low potency will account for a larger fraction of the total 
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than drugs with high potency, and that the combined products may also change their market 
figure. In our study we did not observe any combination so our figures could not be affected 
by such an utilization data. We also did not observe significant changes in the prices per 
milligram for the medicines with different potency, thus this is not also the case for 
consideration. 
The international prices comparison per milligrams of active substance could be used by the 
regulatory authorities.  Grootendorst (2001) analysed the impact of referenced - based pricing 
on nitrates usage and cost reduction by using also the cost per milligram. Similar approach 
was found useful in case of comparison of the medicines prices for particular therapeutic 
groups (Wang 2008), which is also the case in our study.  
The fact that we could not establish strong evidences supporting our second hypothesis could 
be explained with the short period of observation and slow entrance of generic medicines in 
the positive drug list of the National Health Insurance Fund.  
Generic competitors were found for only 8 out of 20 compared INNs and for 4 of them 
(ramipril, pravastatin, atorvastatin, losartan) only one competitor that limits the evaluation of 
the impact of generic competition on prices existed. We didn’t analyse the way the 
pharmaceutical laboratories communicate with the prescribers, which can also have an effect 
on the market. 
Further studies should be organised to evaluate the changes in prices during a longer period, 
when more generic competitors will be available in the country. The national generic 
medicines policy is also of importance as it stimulates the medicines’ prices competition.  
 
Conclusion  
There are two main conclusions from our study. The first one is that for the therapeutic 
groups, which include a lot of similar molecules, it is important to consider the competition 
between the molecules and not only the generic entrance. Originating pharmaceutical 
companies seem to compete among themselves at a therapeutic level and with generic 
companies at a price level.  
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The second conclusion is that the introduction of generic medicines did not affect the mean 
market prices immediately, which means the market needs more than 3 years of stronger 
competition to benefit.  
From the managerial point of view, it is necessary to point out that if the government wants to 
benefit from the generic drug policy, and thus to reduce the medicines prices in the country, it 
should create a stronger supporting environment affecting all the participants in the 
pharmaceutical sector in the country.  
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Table 1: Results of the Kolmogorov Smirnov test  
INN 
Sales data 
(mg) 
2005 
Sales data 
(mg) 
2006 
Sales data 
(mg) 
2007 
K-S  
2006/2005 K-S 2007/2006 
enalapril 1906795530 2287185280 2362110040 
 
 
Null 
hypothesis 
rejected 
 
Null  
hypothesis 
rejected 
lisinopril 47860510 94173850 154909420 
perindopril 14378880 19729440 23778840 
ramipril 5880420 29455406 55117400 
quinapril 47253900 96471300 68185500 
fosinopril 23618840 47761840 56553000 
trandolapril 3322444 6061288 7445446 
cilasapril   553630 3979220 
benazepril   692160 3899840 
            
INN 
Sales data 
(mg) 
2005 
Sales data 
(mg) 
2006 
Sales data 
(mg) 
2007 
K-S  
2006/2005 K-S 2007/2006 
simvastatin 13140540 26303860 125098060 
 
Null 
hypothesis 
rejected 
 
Null  
hypothesis 
rejected 
lovastatin 199510800 310969800 300126000 
pravastatin 5301900 9335100 12384300 
fluvastatin 81453120 84938560 68862080 
atorvastatin 16486500 31483800 36445200 
rosuvastatin  157360 4523400 
            
INN 
Sales data 
(mg) 
2005 
Sales data 
(mg) 
2006 
Sales data 
(mg) 
2007 
K-S  
2006/2005 K-S 2007/2006 
losartan 15715000 196378000 485893800 
 
 
Null 
hypothesis 
rejected 
 
 
Null 
hypothesis 
rejected 
valsartan 58464000 70936320 68051200 
telmisartan 169261120 225245440 207121600 
irbesartan 231000 252000 0 
eprosartan 28089600 143152800 131695200 
 
 
 
 
 
 
 
Table
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Table 2: Results of the z-test analysis 
INN 
% mg 
sales 
2005 
% mg 
sales 
2006 
% mg 
sales 
2007 
z-test 
value 
2006/200
5 
Stat sign 
difference 
z-test 
value 
2007/200
6 
Stat sign 
difference 
enalapril 93.05 88.58 86.34 141.26 Yes 97.70 Yes 
lisinopril 2.34 3.65 5.66 14.10 Yes 22.32 Yes 
perindopril 0.70 0.76 0.87 0.99 No 1.08 No 
ramipril 0.29 1.14 2.01 181.01 Yes 306.23 Yes 
quinapril 2.31 3.74 2.49 14.07 Yes 13.61 Yes 
fosinopril 1.15 1.85 2.07 217.26 Yes 72.54 Yes 
trandolapril 0.16 0.23 0.27 -0.01 No 36.23 Yes 
cilasapril   0.02 0.15     16.09 Yes 
benazepril   0.03 0.14     17.83 Yes 
                
INN 
% mg 
sales 
2005 
% mg 
sales 
2006 
% mg 
sales 
2007 
z-test 
value 
2006/200
5 
Stat sign 
difference 
z-test 
value 
2007/200
6 
Stat sign 
difference 
simvastatin 4.16 5.68 22.85 6.30 Yes 105.43 Yes 
lovastatin 63.16 67.14 54.82 29.32 Yes 96.19 Yes 
pravastatin 1.68 2.02 2.26 40.50 Yes 99.91 Yes 
fluvastatin 25.79 18.34 12.58 1247.00 Yes 846.22 Yes 
atorvastatin 5.22 6.80 6.66 217.43 Yes 16.39 Yes 
rosuvastatin   0.03 0.83     31.085 Yes 
                
INN 
% mg 
sales 
2005 
% mg 
sales 
2006 
% mg 
sales 
2007 
z-test 
value 
2006/200
5 
Stat sign 
difference 
z-test 
value 
2007/200
6 
Stat sign 
difference 
losartan 5.78 30.88 54.43 2115.57 Yes 5447.45 Yes 
valsartan 21.51 11.15 7.62 1699.95 Yes 688.75 Yes 
telmisartan 62.28 35.42 23.20 5320.95 Yes 3823.96 Yes 
irbesartan 0.09 0.04   -0.05 No     
eprosartan 10.34 22.51 14.75 1550.23 Yes 1683.29 Yes 
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Table 3. Differences among the prices among the therapeutic competitors and among the 
years (Results of the two-way ANOVA analysis) 
 
 
Therapeutic 
group 
Prices differences 
among the 
therapeutic 
competitors 
Statistical 
significance 
Differences 
among the prices 
during the years 
Statistical 
significance 
ACE inhibitors p< 0.05 Yes p > 0.05 No 
Statins p< 0.05 Yes p > 0.05 No 
Sartans p< 0.05 Yes p > 0.05 No 
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Table 4: Differences among INN prices during the years (one way ANOVA analysis) 
    2005     2006     2007    One-way ANOVA 
INN 
N 
dosage 
forms  
Mean  
price 
mg  
(BGN) SD 
N 
dosage 
forms  
Mean  
price 
mg 
(BGN) SD 
N 
dosage 
forms  
Mean 
price 
mg 
(BGN) SD  
enalapril 33 0.0188 0.012688 42 0.017 0.011871 39 0.0192 0.021205 p > 0.05 
lisinopril 15 0.0427 0.015337 18 0.0389 0.013672 15 0.0192 0.021205 p < 0.05 
perindopril 2 0.165 0.007071 2 0.16 0 2 0.15 0.014142 p > 0.05 
ramipril 2 0.1 0 2 0.1233 0.068069 3 0.0833 0.028868 p > 0.05 
quinapril 2 0.035 0.00707 2 0.185 0.205061 2 0.035 0.007071 p > 0.05 
fosinopril 2 0.035 0.007071 2 0.035 0.007071 2 0.03 0.014142 p > 0.05 
trandolapril 2 0.925 0.841457 2 0.64 0.579828 2 0.62 0.579828 p > 0.05 
cilasapril   0     2 0.22 0.070711 2 0.18 0.070711 p > 0.05 
benazepril  0     1 0.04 . 1 0.05   p > 0.05 
                     
INN 
N 
dosage 
forms 
Mean 
Price 
mg 
(BGN) SD 
N 
dosage 
forms  
Mean 
price 
mg 
(BGN) SD 
N 
dosage 
forms  
Mean 
price 
mg 
(BGN) SD  
simvastatin 6 0.12 0.093595 10 0.12 0.093595 10 0.035 0.010801 p > 0.05 
lovastatin 4 0.0125 0.005 7 0.0125 0.005 4 0.01 0.01 p > 0.05 
pravastatin 4 0.0775 0.062383 4 0.0775 0.062383 2 0.03 0.014142 p > 0.05 
fluvastatin 1 0.03 . 1 0.03 . 1 0.03 . p > 0.05 
atorvastatin 5 0.096 0.039115 5 0.096 0.039115 5 0.0657 0.030472 p > 0.05 
rosuvastatin 0     2 0.096 0.039115 2     p > 0.05 
                     
INN 
N 
dosage 
forms 
Mean 
Price 
mg 
(BGN) SD 
N 
dosage 
forms  
Mean 
 price 
mg 
(BGN) SD 
N 
dosage 
forms  
Mean 
price 
mg 
(BGN) SD  
losartan 2     2     2      
valsartan 1     1     1      
telmisartan 1     1     1      
irbesartan 2     2      0      
eprosartan 1     1     1      
  7 0.0121 0.008335 7 0.0285 0.030872 5 0.0174 0.007335 p > 0.05 
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INN 
2005  
sales 
in kg 
% 
mg 
sale
s 
N 
trade 
names 
N 
dosage 
forms 
Mean price 
mg 2005 
BGN SD 
2006  
sales  
in kg 
% 
mg 
sale
s 
N 
trade 
names 
N 
dosage 
sales 
Mean  
price mg  
2006 BGN SD 
2007 
sales  
in kg 
% mg 
sales 
N 
trade 
names 
N 
dosage 
 forms 
Mean 
price mg 
2007 BGN SD 
enalapril 1906796 93.1 8 33 0.0188 0.013 2287185 88.6 11 42 0.017 0.012 2362110 86.34 11 39 0.01923 0.021 
lisinopril 47861 2.34 5 15 0.0427 0.02 94174 3.65 6 18 0.03889 0.014 154909 5.66 5 15 0.01923 0.021 
perindopril 14379 0.70 1 2 0.165 0.001 19729 0.76 1 2 0.16 0 23779 0.87 1 2 0.15 0.014 
ramipril 5881 0.29 1 2 0.1 0 29456 1.14 1 2 0.12333 0.068 55117 2.01 2 3 0.08333 0.029 
quinapril 47254 2.31 1 2 0.035 0.007 96471 3.74 1 2 0.185 0.205 68186 2.49 1 2 0.035 0.007 
fosinopril 23619 1.15 1 2 0.035 0.007 47762 1.85 1 2 0.035 0.007 56553 2.07 1 2 0.03 0.014 
trandolapril 3323 0.16 1 2 0.925 0.841 6061 0.23 1 2 0.64 0.580 7445 0.27 1 2 0.62 0.579 
cilasapril   0   0  0 0   0  0 554 0.02 1 2 0.22 0.071 3979 0.15 1 2 0.18 0.071 
benazepril   0   0  0  0  0  0 692 0.03 1 1 0.04 . 3900 0.14 1 1 0.05   
 SUMM 2049113 100         2582084 100         2735978 100         
                                      
INN 
2005 
sales  
in kg 
% 
mg 
sale
s 
N 
trade 
names 
N 
dosage 
forms 
Mean price  
mg 2005 SD 
2006 
sales 
in kg 
% 
mg 
sale
s 
N 
trade 
names 
N 
dosage 
forms 
Mean 
price mg 
2006 BGN SD 
2007 
sales 
in kg 
% mg 
sales 
N 
trade 
names 
N 
dosage 
forms 
Mean 
price mg 
2007 BGN SD 
simvastatin 13141 4.16 1 6 0.12 0.094 26304 5.68 3 10 0.06917 0.081 125098 22.85 3 10 0.035 0.010 
lovastatin 199511 63.2 2 4 0.013 0.005 310970 67.2 4 7 0.01143 0.004 300126 54.82 2 4 0.01 0 
pravastatin 5302 1.68 2 4 0.078 0.062 9335 2.02 2 4 0.0925 0.064 12384 2.26 1 2 0.03 0.014 
fluvastatin 81453 25.8 1 1 0.03 . 84939 18.3 1 1 0.03 . 68862 12.58 1 1 0.03 . 
atorvastatin 16487 5.22 2 5 0.096 0.039 31484 6.80 2 5 0.078 0.054 36445 6.66 2 5 0.06571 0.031 
rosuvastatin  0  0  0 0     157 0.03 1 2 0.16 0.028 4523 0.83 1 2  0.16  . 
 SUMM 315894 100         463189 100         547438 100         
                                      
INN 
2005 
sales 
in kg 
% 
mg 
sale
s 
N 
trade 
names 
N 
dosage 
forms 
Mean price 
mg 2005 
BGN SD 
2006 
sales 
in kg 
% 
mg 
sale
s 
N 
trade 
names 
N 
dosage 
forms 
Mean 
price mg 
2006 BGN SD 
2007 
sales 
in kg 
% 
sales 
N 
trade 
names 
N 
dosage 
forms 
Mean 
price mg 
2007 BGN SD 
losartan 15715 5.78 2 2     196378 30.9 2 2     485894 54.43 2 2     
valsartan 58464 21.5 1 1     70936 11.2 1 1     68051 7.62 1 1     
telmisartan 169261 62.3 1 1     225245 35.4 1 1     207122 23.20 1 1     
irbesartan 231 0.09 1 2     252 0.04 1 2     0    0  0     
eprosartan 28090 10.3 1 1     143153 22.5 1 1     131695 14.75 1 1     
 SUMM 271761 100     0.012 0.008 635965 100     0.0285 0.031 892762 100     0.0174 0.007 
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Figure 1: Relative market share of ACE inhibitors sales during 2005, 2006 and 2007. 
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Figure 2: Relative market share of sartans sales during 2005, 2006 and 2007. 
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 Figure 3: Relative market share of statins sales during 2005, 2006 and 2007. 
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